National marketing authorization in Germany for novel cell therapy
RHEACELL has been granted national marketing authorization in Germany (§4b of the German Medicinal Products Act) for its cell therapy product AMESANAR®, produced by TICEBA, for the use in patients with chronic wounds.
The company RHEACELL: our goal is to be the leader in the field of stem cell-based drugs
RHEACELL is a biopharmaceutical company dedicated to developing drugs based on a platform technology of ABCB5-positive (ABCB5+) mesenchymal stem cells.
Strong clinical pipeline
Together with world leading experts, RHEACELL develops clinical research programs focusing on patients with unmet medical need, e.g. in rare pediatric and dermatological diseases accompanied and/or based on systemic inflammation.
Pediatric Investigation Plan (PIP) approved by PDCO (EMA)
The European Medicines Agency (EMA) has approved the pediatric investigation plan for our Epidermolysis Bullosa program, bringing us one step closer to filing for marketing authorization.
Off the shelf manufacturing process serving market needs
RHEACELL has exclusive access to TICEBA's stem cell manufacturing know-how: a company that is specialized in high-throughput, off-the-shelf GMP-manufactured stem cells.
Worldwide exclusive patents with freedom to operate
RHEACELL is an exclusive licensee of the full ABCB5 patent portfolio from Boston Children’s Hospital, a teaching affiliate of Harvard Medical School, Boston, Massachusetts. Several of these are co-owned by RHEACELL.
Founding partners: a joint-venture between Müller und TICEBA
The RHEACELL development program is supported by the Müller Holding with an investment of 60 Mio. Euro and TICEBA, a specialist in stem cell manufacturing.
Key opinion leaders as partners for clinical research programs
RHEACELL's development programs are supported in collaboration with world renowned scientists and clinicians.
R&D is the key of our success. Specializing in stem cell-based drugs and taking this route from the outset has enabled us to bring quality and safety into a new research field.
Through our unique stem cell technology, we are bringing new healing opportunities to those who would otherwise have none. We are dedicated to developing drugs for those hitherto incurable serious chronic and hereditary diseases, which cannot be cured by conventional therapies.
Day in, day out, we passionately and resolutely work on innovative stem cell therapies for inflammatory and degenerative diseases. We discover new ways by researching in greater depth, thinking ahead, rechecking repeatedly and proving the knowledge we have gained from all over the world. For we know that research can only be as good as its implementation. The progress is solid only if it reaches patients via a systematic, rapid and safe pipeline. This is our conviction and our particular concern. Every Single Day.